Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability StudyJacques Bonneterre, Mia von Euler, Mark L. Steinberg et al.|Journal of Clinical Oncology|2000Cited by 840
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trialJ.F.R. Robertson, Matthew J. Ellis|The Lancet|2016Cited by 599
Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST StudyJ.F.R. Robertson, Matthew J. Ellis, Antonio Llombart‐Cussac et al.|Journal of Clinical Oncology|2009Cited by 312
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST StudyMatthew J. Ellis, J.F.R. Robertson, Antonio Llombart‐Cussac et al.|Journal of Clinical Oncology|2015Cited by 239
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ studyJ.F.R. Robertson, Matthew J. Ellis, Justin P.O. Lindemann et al.|Breast Cancer Research and Treatment|2012Cited by 172